Moving forward with Takeda's live chimeric tetravalent dengue vaccine

Several decades of dengue vaccine research have shown how challenging it is to develop a highly efficacious vaccine that protects against all four dengue serotypes (DENV-1–4) for people of all ages. In light of the rapidly rising incidence of dengue virus infection, now estimated to affect about 100...

Full description

Saved in:
Bibliographic Details
Main Author: Wilder-Smith, Annelies
Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
Format: Article
Language:English
Published: 2017
Subjects:
Online Access:https://hdl.handle.net/10356/83617
http://hdl.handle.net/10220/42732
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
Description
Summary:Several decades of dengue vaccine research have shown how challenging it is to develop a highly efficacious vaccine that protects against all four dengue serotypes (DENV-1–4) for people of all ages. In light of the rapidly rising incidence of dengue virus infection, now estimated to affect about 100 million individuals per year,1 the approval of the first dengue vaccine developed by Sanofi Pasteur (CYD-TDV) was a welcome step forward.2 However, the first vaccine does not present a simple solution.